Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Anaerobe ; 62: 102149, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31940467

ABSTRACT

The anaerobic bacterium Clostridioides difficile is the leading cause of antibiotic-associated diarrhea that can culminate in life-threating colitis. During the C. difficile infection (CDI), C. difficile produces toxins that generate the clinical symptoms of the disease, and produce spores, which persist in the host during antibiotic treatment and can cause recurrent CDI (R-CDI). In this work, we aimed to compare three antibiotic regimens in the susceptibility of mice to CDI and R-CDI (i.e., antibiotic cocktail followed by clindamycin, 5 days of cefoperazone and 10 days of cefoperazone) with three different C. difficile isolates (i.e., strains 630; R20291, and VPI 10463). We observed that the severity of the clinical symptoms of CDI and R-CDI was dependent on the antibiotic treatment used to induce C. difficile-susceptibility, and that the three strains generated a different onset to diarrhea and weight loss in mice that were administrated with the same antibiotic treatment and which differed in comparison to the effect previously reported by other research groups. Our results suggest that, in our experimental conditions, in those animals treated with antibiotic cocktail followed by clindamycin, infection with strain R20291 had the highest diarrhea manifestation in comparison to strains 630 and VPI 10463. In animals treated with cefoperazone for 5 days, infection with strains R20291 or 630 had the highest diarrhea manifestation in comparison to VPI 10463, while in animals treated with cefoperazone for 10 days, infection with strain R20291 or VPI 10463, but not 630, had the highest diarrhea manifestation.


Subject(s)
Anti-Bacterial Agents/pharmacology , Clostridioides difficile/drug effects , Clostridium Infections/microbiology , Animals , Anti-Bacterial Agents/therapeutic use , Chlorocebus aethiops , Clostridium Infections/diagnosis , Clostridium Infections/drug therapy , Disease Models, Animal , Feces/microbiology , Mice , Recurrence , Treatment Outcome , Vero Cells
2.
Future Microbiol ; 13: 1271-1281, 2018 09.
Article in English | MEDLINE | ID: mdl-30238771

ABSTRACT

AIM: To evaluate the effect on the nonsteroidal anti-inflammatory drug indomethacin on Clostridium difficile infection (CDI) severity. MATERIALS & METHODS: Indomethacin was administered in two different mouse models of antibiotic-associated CDI in two different facilities, using a low and high dose of indomethacin. RESULTS: Indomethacin administration caused weight loss, increased the signs of severe infection and worsened histopathological damage, leading to 100% mortality during CDI. Indomethacin-treated, antibiotic-exposed mice infected with C. difficile had enhanced intestinal inflammation with increased expression of KC, IL-1ß and IL-22 compared with infected mice unexposed to indomethacin. CONCLUSION: These results demonstrate a negative impact of nonsteroidal anti-inflammatory drugs on antibiotic-associated CDI in mice and suggest that targeting the synthesis or signaling of prostaglandins might be an approach to ameliorating the severity of CDI.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Clostridioides difficile , Clostridium Infections/drug therapy , Clostridium Infections/pathology , Indomethacin/adverse effects , Intestines/pathology , Severity of Illness Index , Animals , Anti-Bacterial Agents/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Disease Models, Animal , Indomethacin/administration & dosage , Interleukin-1beta/metabolism , Interleukins/metabolism , Intestines/drug effects , Mice , Mice, Inbred C57BL , Prostaglandin Antagonists/adverse effects , Prostaglandins/biosynthesis , Risk Factors , Weight Loss , Interleukin-22
SELECTION OF CITATIONS
SEARCH DETAIL